Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Industrials ETF

307.21
-3.9600-1.27%
Post-market: 307.210.00000.00%19:49 EDT
Volume:115.08K
Turnover:35.54M
Market Cap:6.89B
PE:7.19
High:311.09
Open:310.02
Low:306.58
Close:311.17
52wk High:345.71
52wk Low:213.26
Shares:22.44M
Float Shares:22.44M
Volume Ratio:1.08
T/O Rate:0.51%
Dividend:3.12
Dividend Rate:1.02%
EPS(TTM):42.70
EPS(LYR):42.70
ROE:11.54%
ROA:0.79%
PB:1.15
PE(LYR):7.19

Loading ...

Exchange-Traded Funds Rise as US Equities Trade Mixed After Midday

MT Newswires Live
·
Nov 15, 2025

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Expected Economic Data Gaps

MT Newswires Live
·
Nov 13, 2025

Decline in Magnificent-7 Stocks Leaves Exchange-Traded Funds, US Equities Mixed

MT Newswires Live
·
Nov 13, 2025

VIS 1H Net Y414.00M Vs Net Y640.00M

Dow Jones
·
Nov 12, 2025

Exchange-Traded Funds Rise as US Equities Trade Mixed After Midday

MT Newswires Live
·
Nov 12, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes of Government Reopening

MT Newswires Live
·
Nov 10, 2025

Exchange-Traded Funds Trend Lower as US Equities Drop After Midday

MT Newswires Live
·
Nov 08, 2025

Exchange-Traded Funds Rise as US Equities Trend Higher After Midday

MT Newswires Live
·
Nov 06, 2025

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Tech Rally Doubts

MT Newswires Live
·
Nov 04, 2025

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid AI Demand, US-China Deal Hope

MT Newswires Live
·
Nov 03, 2025

What Everest Medicines (SEHK:1952)'s Exclusive VIS-101 Ophthalmology License Means for Shareholders

Simply Wall St.
·
Nov 02, 2025

Everest Medicines (SEHK:1952): Valuation Insights Following Exclusive VIS-101 Ophthalmology Deal

Simply Wall St.
·
Nov 01, 2025

Exchange-Traded Funds Lower, US Equities Mixed After Midday

MT Newswires Live
·
Nov 01, 2025

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

prnewswire
·
Oct 30, 2025

EVEREST MED (01952) Secures Exclusive Rights to Ophthalmic Bispecific Drug VIS-101, Entering $40 Billion Blue Ocean Market

Stock News
·
Oct 30, 2025

EVEREST MED (01952) Enters Agreement with VISARA for Development and Commercialization of VIS-101 in Greater China and Other Asian Markets

Stock News
·
Oct 30, 2025

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

GlobeNewswire
·
Oct 30, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Interest Rate Cut Hopes

MT Newswires Live
·
Oct 29, 2025

Exchange-Traded Funds, US Equities Rise After Midday

MT Newswires Live
·
Oct 28, 2025

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Potential CPI Report

MT Newswires Live
·
Oct 24, 2025